These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 30454706)

  • 1. Combinatory inhibition of TRIM65 and MDM2 in lung cancer cells.
    Chen G; Zhou T; Liu Y; Yu Z
    Biochem Biophys Res Commun; 2018 Nov; 506(3):698-702. PubMed ID: 30454706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TRIM65 negatively regulates p53 through ubiquitination.
    Li Y; Ma C; Zhou T; Liu Y; Sun L; Yu Z
    Biochem Biophys Res Commun; 2016 Apr; 473(1):278-282. PubMed ID: 27012201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nutlin sensitizes lung carcinoma cells to interferon-alpha treatment in MDM2-dependent but p53-independent manner.
    Shuvalov O; Kizenko A; Shakirova A; Fedorova O; Petukhov A; Aksenov N; Vasileva E; Daks A; Barlev N
    Biochem Biophys Res Commun; 2018 Jan; 495(1):1233-1239. PubMed ID: 29175211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Knockdown of TRIM65 inhibits lung cancer cell proliferation, migration and invasion: A therapeutic target in human lung cancer.
    Wang XL; Shi WP; Shi HC; Lu SC; Wang K; Sun C; He JS; Jin WG; Lv XX; Zou H; Shu YS
    Oncotarget; 2016 Dec; 7(49):81527-81540. PubMed ID: 27829229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiosensitization of lung cancer by nutlin, an inhibitor of murine double minute 2.
    Cao C; Shinohara ET; Subhawong TK; Geng L; Kim KW; Albert JM; Hallahan DE; Lu B
    Mol Cancer Ther; 2006 Feb; 5(2):411-7. PubMed ID: 16505116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cooperation of Nutlin-3a and a Wip1 inhibitor to induce p53 activity.
    Sriraman A; Radovanovic M; Wienken M; Najafova Z; Li Y; Dobbelstein M
    Oncotarget; 2016 May; 7(22):31623-38. PubMed ID: 27183917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The MDM2-inhibitor Nutlin-3 synergizes with cisplatin to induce p53 dependent tumor cell apoptosis in non-small cell lung cancer.
    Deben C; Wouters A; Op de Beeck K; van Den Bossche J; Jacobs J; Zwaenepoel K; Peeters M; Van Meerbeeck J; Lardon F; Rolfo C; Deschoolmeester V; Pauwels P
    Oncotarget; 2015 Sep; 6(26):22666-79. PubMed ID: 26125230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The hydrophobically-tagged MDM2-p53 interaction inhibitor Nutlin-3a-HT is more potent against tumor cells than Nutlin-3a.
    Nietzold F; Rubner S; Berg T
    Chem Commun (Camb); 2019 Nov; 55(95):14351-14354. PubMed ID: 31720601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting negative regulation of p53 by MDM2 and WIP1 as a therapeutic strategy in cutaneous melanoma.
    Wu CE; Esfandiari A; Ho YH; Wang N; Mahdi AK; Aptullahoglu E; Lovat P; Lunec J
    Br J Cancer; 2018 Feb; 118(4):495-508. PubMed ID: 29235570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Restoration of p53 pathway by nutlin-3 induces cell cycle arrest and apoptosis in human rhabdomyosarcoma cells.
    Miyachi M; Kakazu N; Yagyu S; Katsumi Y; Tsubai-Shimizu S; Kikuchi K; Tsuchiya K; Iehara T; Hosoi H
    Clin Cancer Res; 2009 Jun; 15(12):4077-84. PubMed ID: 19509161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Downregulation of cyclin D1 sensitizes cancer cells to MDM2 antagonist Nutlin-3.
    Yang P; Chen W; Li X; Eilers G; He Q; Liu L; Wu Y; Wu Y; Yu W; Fletcher JA; Ou WB
    Oncotarget; 2016 May; 7(22):32652-63. PubMed ID: 27129163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic potential of Mdm2 inhibition in malignant germ cell tumours.
    Bauer S; Mühlenberg T; Leahy M; Hoiczyk M; Gauler T; Schuler M; Looijenga L
    Eur Urol; 2010 Apr; 57(4):679-87. PubMed ID: 19560254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nutlin-3 inhibits the NFkappaB pathway in a p53-dependent manner: implications in lung cancer therapy.
    Dey A; Wong ET; Bist P; Tergaonkar V; Lane DP
    Cell Cycle; 2007 Sep; 6(17):2178-85. PubMed ID: 17786042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Actinomycin D and nutlin-3a synergistically promote phosphorylation of p53 on serine 46 in cancer cell lines of different origin.
    Zajkowicz A; Gdowicz-Kłosok A; Krześniak M; Ścieglińska D; Rusin M
    Cell Signal; 2015 Sep; 27(9):1677-87. PubMed ID: 25989210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. On p53 revival using system oriented drug dosage design.
    Haseeb M; Azam S; Bhatti AI; Azam R; Ullah M; Fazal S
    J Theor Biol; 2017 Feb; 415():53-57. PubMed ID: 27979498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma.
    Patterson DM; Gao D; Trahan DN; Johnson BA; Ludwig A; Barbieri E; Chen Z; Diaz-Miron J; Vassilev L; Shohet JM; Kim ES
    Angiogenesis; 2011 Sep; 14(3):255-66. PubMed ID: 21484514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of p53-murine double minute 2 interaction by nutlin-3A stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin lymphoma.
    Drakos E; Thomaides A; Medeiros LJ; Li J; Leventaki V; Konopleva M; Andreeff M; Rassidakis GZ
    Clin Cancer Res; 2007 Jun; 13(11):3380-7. PubMed ID: 17545546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclin-dependent kinase inhibitors sensitize tumor cells to nutlin-induced apoptosis: a potent drug combination.
    Cheok CF; Dey A; Lane DP
    Mol Cancer Res; 2007 Nov; 5(11):1133-45. PubMed ID: 18025259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pre-clinical efficacy and synergistic potential of the MDM2-p53 antagonists, Nutlin-3 and RG7388, as single agents and in combined treatment with cisplatin in ovarian cancer.
    Zanjirband M; Edmondson RJ; Lunec J
    Oncotarget; 2016 Jun; 7(26):40115-40134. PubMed ID: 27223080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TRIM65 is a potential oncogenic protein via ERK1/2 on Jurkat and Raji cells: A therapeutic target in human lymphoma malignancies.
    Wang J; Liang X; Yu T; Xu YL; Xu LH; Zhang XJ; Ma J; Wang YR; He SL
    Cell Biol Int; 2018 Nov; 42(11):1503-1510. PubMed ID: 30039885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.